Can incretin-based therapy and SGLT-2 inhibitors may be useful in the treatment of diabetes type 1?

被引：0
作者：
Rozanska, Paulina [1 ]
Wierusz-Wysocka, Bogna [1 ]
Zozulinska-Ziolkiewicz, Dorota [1 ]
机构：
[1] Uniwersytetu Med Karola Marcinkowskiego Poznaniu, Katedra & Klin Chorob Wewnetrznych & Diabetol, Poznan, Poland
来源：
CLINICAL DIABETOLOGY | 2015年 / 4卷 / 04期
关键词：
diabetes mellitus type 1; incretin-based therapy; SGLT-2; inhibitors;
D O I：
10.5603/DK.2015.0015
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
It is known, that insulin therapy is essential in the treatment of type 1 diabetes. Insulin therapy has been related with some side effects such as hypoglycemia and weight gain, strongly connected with insulin resistance. Therefore the metformin is used sometimes as additive therapy In patients with type 1 diabetes. Recently, glukagon-like peptide 1 (GLP-1) analogs, dipeptydyl peptidase 4 (DPP-4) inhibitors and sodium glucose co-transporter 2 inhibitors (SGLT-2) has been raported to be beneficial for the glycemic control in type 1 diabetic.
引用
收藏
页码：147 / 151
页数：5
相关论文
共 50 条
  • [21] SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes
    Davila, Esteban
    Mccormack, James
    ACADEMIC EMERGENCY MEDICINE, 2024, 31 (04) : 408 - 411
  • [22] The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure
    Riggs, Kayla
    Ali, Hiba
    Taegtmeyer, Heinrich
    Gutierrez, Absalon D.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2015, 13 (07) : 292 - 297
  • [23] Partnering with Patients to Improve Therapeutic Outcomes: Incretin-Based Therapy for Type 2 Diabetes
    Nadeau, Daniel A.
    POSTGRADUATE MEDICINE, 2010, 122 (03) : 7 - 15
  • [24] The evolving place of incretin-based therapies in type 2 diabetes
    Gallwitz, Baptist
    PEDIATRIC NEPHROLOGY, 2010, 25 (07) : 1207 - 1217
  • [25] Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Nauck, M.
    Smith, U.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (04) : 513 - 523
  • [26] SGLT2 inhibitors in the treatment of type 2 diabetes
    Hasan, Farhad M.
    Alsahli, Mazen
    Gerich, John E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 104 (03) : 297 - 322
  • [27] SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus
    Ozel, Hasan Fehmi
    Alpay, Suheda
    Asker, Emre
    Gultekin, Elif Sidal
    Kazdagli, Hasan
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2025, 39 (05)
  • [28] Incretin-based therapies in type 2 diabetes: A review of clinical results
    Bosi, Emanuele
    Lucotti, Pietro
    Setola, Emanuela
    Monti, Lucilla
    Piatti, Pier Marco
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 82 : S102 - S107
  • [29] GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns
    Dimitriadis, George D.
    Lambadiari, Vaia
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04) : E52 - E53
  • [30] Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
    Dabrowski, Mariusz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) : 1 - 18
12345